CEBRX | MEDCX | CEBRX / MEDCX | |
Total Expense Ratio | 0.75 | 1.81 | 41% |
Annual Report Gross Expense Ratio | 0.75 | 1.82 | 41% |
Fund Existence | 13 years | 23 years | - |
Gain YTD | 2.460 | 1.169 | 210% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 1000 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 279M | 6.99B | 4% |
Annual Yield % from dividends | 5.54 | 5.77 | 96% |
Returns for 1 year | 6.76 | 5.43 | 124% |
Returns for 3 years | 19.59 | 16.47 | 119% |
Returns for 5 years | 13.76 | 7.77 | 177% |
Returns for 10 years | 33.62 | 21.43 | 157% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
OIGAX | 34.73 | N/A | N/A |
Invesco Oppenheimer International Gr A | |||
FICGX | 12.17 | N/A | N/A |
Cantor Fitzgerald Large Cap Fcs Cl A | |||
BMCRX | 24.67 | N/A | N/A |
BlackRock Advantage Large Cap Gr R | |||
TNVRX | 16.12 | N/A | N/A |
1290 GAMCO Small/Mid Cap Value R | |||
EMWLX | 17.34 | N/A | N/A |
Lord Abbett Emerging Markets Equity R6 |